Biolase, Inc. · OTC:BIOLQ
Biolase — Rodman & Renshaw 20th Annual Global Investment Conference 2018
28 slides from Biolase's conference presentation, Sep 5, 2018
Slide 1: Advancing Dentistry
Exhibit 99.1 Advancing Dentistry Rodman & Renshaw th 20 Annual Global Investment Conference September 4-6, 2018 NASDAQ CM:BIOLExhibit 99.1 Advancing Dentistry Rodman & Renshaw th 20 Annual Global Investment Conference September 4-6, 2018 NASDAQ CM:BIOL
Slide 2: BIOLASE at a Glance – Global Leader in Dental Lasers
BIOLASE at a Glance – Global Leader in Dental Lasers ~37,600 318 ~200 Issued or Pending Employees Lasers Sold Globally Patents Worldwide % of 80 >50 3 4 FDA-Cleared Indications Share of Global All-tissue Lasers Sold for Waterlase® and Epic Dental Laser Globally are Market Waterlase % 97 ~30 Million
Slide 3: BIOLASE – Highs and Lows
BIOLASE – Highs and Lows Highs • Brand value • Dental market leadership • Technology and new product leadership • Committed users • Expanding base of new customers • Large intellectual property portfolio Lows • Management disruptions • A fundamental miss on adoption of technology • Historical custom
Slide 4: BIOLASE – The Continuing Story
BIOLASE – The Continuing Story • Late-stage turnaround • Significantly improved product, support and education reliability in past 3 years • Board enhanced with addition of extensive dental expertise • Southern CA Initiative for Model Market program • CEO transition – Todd A. Norbe, joined the Board
Slide 5: BIOLASE – The Continuing Story, 2018 Initiatives
BIOLASE – The Continuing Story, 2018 Initiatives Complete sales team transformation re- Establish community service relationships boot • Partnered with Healthy Smiles for Kids • In process, recent sales hires are of Orange County and TeamSmile (LA among our best performing Chargers) to improve denta
Slide 6: Model Market Initiative – Focus on Demonstrating Adoption in the Marketplace
Model Market Initiative – Focus on Demonstrating Adoption in the Marketplace • Started in late 2017, to test different sales and marketing tactics to increase general laser awareness, ultimately sales ‒ Focus resources in Los Angeles and Orange County ‒ 10% of dentists in U.S., largest presence of D
Slide 7: Model Market – Early Results to Date
Model Market – Early Results to Date • 2Q18 all-tissue laser sales increased ~200% Y-O-Y ‒ >70% confidence pipeline for Model Market increased 8X Y-O-Y • Achieved with only 8% of “High Priority” targets contacted ‒ 70-80 contacts per week, ongoing • Media impressions have increased – Biolase Twitter
Slide 8: 2Q18 Overview
2Q18 Overview • Worldwide revenue $12.2 million compared to $12.6 million in 2Q17, which included large one-time buy of non-core imaging products • Excluding 2Q17 one-time non-core imaging revenue, 2Q18 core laser-related product revenue was up 1% Y-O-Y • Worldwide revenue up sequentially >21% from
Slide 9: 2Q18 Overview
2Q18 Overview • Consumables and other revenue increased 12% Y-O-Y, driven by a 6% increase in the U.S. and a 23% increase internationally due largely to the Company’s success in attracting new customers • International revenue increased 13% to $5.0 million Y-O-Y driven by a 7% increase in core denta
Slide 10: Growth Opportunity in Bringing Europe "On Par" with U.S.
Growth Opportunity in Bringing Europe “On Par” with U.S. 68% of 2018 Revenue To-Date from Laser System Sales, 64% of Sales Made in U.S. Royalties 0% Services/Warranties International 13% United States 36% Laser Systems 64% 68% Consumables 13% Revenue by Revenue by Region Category Imaging Systems 6%
Slide 11: Market Opportunity – All-Tissue Lasers
Market Opportunity – All-Tissue Lasers 1 • 176,000 dentists in US & Canada • >1.4 Million dentists in 134 other countries – Rapid growth in emerging economies 2 – e.g. China, India and Indonesia • Current market penetration ‒ ~7.0% of dental practices in US ‒ ~1.4% worldwide • Each 1% increase in ma
Slide 12: BIOLASE Has Dominant Share in All-Tissue Laser Markets
BIOLASE Has Dominant Share in All-Tissue Laser Markets, Market Leadership in Soft-Tissue Lasers All Tissue Lasers Global Share Others Deka 7% 4% J.Morita 9% Types of Dental Lasers Sold - Lifetime Syneron Biolase 11% 52% All Tissue 13% Fotona 14% Soft Tissue 87% Soft Tissue Lasers Global Share Elexxi
Slide 13: A Significant Growth Opportunity
A Significant Growth Opportunity >60 Million People in U.S. Alone Have Gum Disease and Health Risk of Oral-systemic Connection Under-diagnosed, Under-treated, Under-managed 13A Significant Growth Opportunity >60 Million People in U.S. Alone Have Gum Disease and Health Risk of Oral-systemic Connectio
Slide 14: Next Buyers of All-Tissue Lasers?
Next Buyers of All-Tissue Lasers? • Adopt a “wait and see” approach to technology • Base opinions on references from peers • Want simplicity and predictability • Need a clear ROI strategy before adopting new technology • Reluctant to add things that are disruptive to daily practice • More reliant on
Slide 15: Barriers to Adoption?
Barriers to Adoption? • All-tissue lasers have not yet caught on with the greater dental population • Dentists are not laser averse: Diodes have reached >50% penetration 3 Perceptions and Opportunities Hard to Skeptical Expensive Learn Even with more than Despite case reports Integrating and routine
Slide 16: Disrupting Dentistry and Establishing All-Tissue Laser Dentistry as the Standard of Care
Disrupting Dentistry and Establishing All-Tissue Laser Dentistry as the Standard of Care 1. BREAK THE STATUS QUO - Get dentists around the world to perform procedures with lasers that they may be afraid of doing and uncomfortable presenting (selling) to patients… help make every dentist a better den
Slide 17: Dental Drills Vibrate & Create Heat, Heat = Pain
Dental Drills Vibrate & Create Heat, Heat = Pain … There is a better way! “My goal with Waterlase is to develop a generation of children where they can come into the dental office, and they don’t have any fear. I don’t give them any anesthetic and they can go back to school or out to play with no nu
Slide 18: What Patients Say About Waterlase
What Patients Say About Waterlase 18What Patients Say About Waterlase 18
Slide 19: A Growing Full-spectrum Portfolio of Laser Systems and Procedural Consumables
A Growing Full-spectrum Portfolio of Laser Systems and Procedural Consumables Waterlase Express™ • New! – Smallest, easiest most cost-effective Waterlase • Vivid HD tablet user interface • Exclusive procedural animations • Rich on-board reference library and Customer Care Button • And more • Most po
Slide 20: Laser Dentistry Can Disrupt the Market
Laser Dentistry Can Disrupt the Market – 1 It Addresses the Challenges Faced by Today’s Dentists • Better patient reported outcomes • Average pay decreasing over Last 10 Years • Dentistry more competitive – The need to standout • Patients becoming consumers and “Review” more • With more competition,
Slide 21: Spreading The Word – New TV Commercial
Spreading The Word – New TV Commercial 21Spreading The Word – New TV Commercial 21
Slide 22: Delivering Better Patient Outcomes
Delivering Better Patient Outcomes Waterlase Laser Dentistry provides an entirely new patient experience with increased comfort and less of the anxiety and pain ordinary dentistry can cause Decreased Increased • Health• Anesthetic • Healing• Scars .. • Discomfort • Esthetics • Tooth preservation• Fe
Slide 23: Dental Lasers – Better Dentistry, Better Business
Dental Lasers – Better Dentistry, Better Business Procedure-based Laser Solutions Enable Professional and Practice Vitality Globally Increased Decreased • Positive outcomes• Complications • Patient excitement• Anxiety • Healing• Chair time • Competitiveness • Local market buzz • Cash flow 23Dental L
Slide 24: Positive Cash Flow – Investment in Patient Outcomes and Business Returns
Positive Cash Flow – Investment in Patient Outcomes and Business Returns Very Few Additional Procedures per Month, Can Upgrade Patient Experience & ROI WL Express Lease Cost: $840/Month New Procedures (of dozens available) & Representative Fee/Reimbursement Avg. (net of consumable cost) No./ Procedu
Slide 25: BIOLASE Stock Data: (NASDAQ CM:BIOL)
BIOLASE Stock Data: (NASDAQ CM:BIOL)* 52 Week Price Range $1.14 - $3.95 Recent Price (August 24, 2018) $1.70 Average Daily Volume (50 Days) 81,954 Common Shares Outstanding (August 6, 2018) 20,596,901 Market Capitalization (August 24, 2018) $35,014,732 *Adjusted for 1 for 5 reverse split of common s
Slide 26: Investment Thesis
Investment Thesis Disrupting Dentistry with Exceptional Laser Technology and Products, World-class Education and Support: • Late-stage turnaround – focused on renewed revenue and profit growth • Strategic pivot to focus on high-value, prevalent and undertreated diseases • Industry-leading innovation
Slide 27: Safe Harbor Statement
Safe Harbor Statement Statements made in this presentation and during discussions with BIOLASE representative’s that refer to BIOLASE’s estimated or anticipated future results or other non-historical facts are forward-looking statements, as are any statements its representatives make concerning BIOL
Slide 28: Questions and Answers
Questions and Answers 28Questions and Answers 28
Biolase — Rodman & Renshaw 20th Annual Global Investment Conference 2018 on 6ix